Article Text

Download PDFPDF
Clinical characteristics–cognitive phenotype
J03 The potential of a composite cognitive score for tracking progression in Huntington's disease
  1. C Frost1,
  2. R Jones1,
  3. I Labuschange2,
  4. M Say3,
  5. D Justo4,
  6. A Coleman5,
  7. E Dumas6,
  8. E 't Hart3,
  9. G Owen3,
  10. A Durr4,
  11. B Leavitt5,
  12. R Roos6,
  13. A O'Regan2,
  14. SJ Tabrizi3,
  15. JC Stout2
  1. 1London School of Hygiene and Tropical Medicine, London, UK
  2. 2School of Psychology and Psychiatry, Monash University, Victoria, Australia
  3. 3UCL Institute of Neurology, University College London, London, UK
  4. 4Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris, France
  5. 5Department of Medical Genetics, University of British Columbia, Vancouver, Canada
  6. 6Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands


Background/Aims We investigated the ability of composite scores developed using statistical models to differentiate progressive cognitive deterioration in Huntington's disease (HD) from natural decline in healthy controls.

Methods Using data from TRACK-HD the optimal combination of 24-month changes in quantitative cognitive measures to differentiate early stage HD individuals from controls was determined using logistic regression. Composite scores were calculated from the parameters of the model. Linear regression models were used to calculate effect sizes (ES) quantifying the difference in longitudinal change in the composite over 24 months between premanifest and early stage HD groups and controls respectively. This ES was compared with those for individual cognitive outcomes and other measures used in HD research. 0.632 bootstrap methodology was used to allow for biases which result from developing and testing models in the same sample.

Results The composite score gave an ES for the difference in rate of 24-month change between early HD and controls of 1.14 (95% CI 0.90 to 1.39): larger than that for any of the individual cognitive outcomes and those for the UHDRS TFC and TMS. Additionally the composite gave a statistically significant difference in the rate of change in premanifest HD compared to controls over 24-months (ES: 0.24; 95% CI 0.04 to 0.44), despite none of the individual cognitive outcomes having statistically significant ES over this period.

Conclusions Composite scores developed using appropriate statistical modelling techniques have the potential to materially reduce required sample sizes for randomised controlled trials.

  • Cognition
  • combinations
  • progression
  • effect sizes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.